https://www.takeda.com/newsroom/newsreleases/2015/sumitomo-dainippon-pharma-co-ltd2-and-takeda-pharmaceutical-company--limited-announce-decision-to-terminate-their-agreement-for-the-joint/
Sumitomo Dainippon Pharma Co. Ltd. and Takeda Pharmaceutical Company Limited Announce Decision to...
Sumitomo Dainippon Pharma Co. Ltd. and Takeda Pharmaceutical Company Limited Announce Decision to Terminate their Agreement for the Joint Development and...
sumitomo dainippon pharmatakeda pharmaceutical company
https://www.prnewswire.com/news-releases/sumitomo-dainippon-pharma-oncology-announces-its-formation-through-merger-of-tolero-and-boston-biomedical-301086491.html
Sumitomo Dainippon Pharma Oncology Announces Its Formation Through Merger of Tolero and Boston...
/PRNewswire/ -- Sumitomo Dainippon Pharma Oncology, Inc. was formed today through the merger of Tolero Pharmaceuticals, Inc., and Boston Biomedical, Inc.,...
sumitomo dainippon pharma
https://www.biospace.com/poxel-and-sumitomo-dainippon-pharma-announce-second-positive-top-line-results-for-imeglimin-phase-3-trial-times-3-in-japan-for-the-treatment-of-type-2-diabetes
Poxel and Sumitomo Dainippon Pharma Announce Second Positive Top-Line Results for Imeglimin Phase 3...
Jun 25, 2019 - Imeglimin in combination with insulin Phase 3 TIMES 3 16-week, double-blind, placebo-controlled, randomized part of the trial met its primary endpoint with a...